Tibor Markus Brunt

Dr. Tibor Markus Brunt

Psychiatry, Amsterdam University Medical Centers, Amsterdam, Noord-Holland, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2015 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
JAJan Van Amsterdam
Jan Van Amsterdam
TBTibor Markus Brunt
Tibor Markus Brunt
WBWim van Den Brink
Wim van Den Brink
Cannabis use is associated with an increased risk of psychosis in vulnerable individuals. Cannabis containing high levels of the partial cannabinoid receptor subtype 1 (CB1) agonist tetrahydrocannabinol (THC) is associated with the induction of psychosis in susceptible subjects and with the development of schizophrenia, whereas the use of cannabis variants with relatively high levels of cannabidiol (CBD) is associated with fewer psychotic experiences. Synthetic cannabinoid receptor agonists (SCRAs) are full agonists and often more potent than THC. Moreover, in contrast to natural cannabis, SCRAs preparations contain no CBD so that these drugs may have a higher psychosis-inducing potential than cannabis. This paper reviews the general toxicity profile and the adverse effects of SCRAs with special emphasis on their psychosis-inducing risk. The review shows that, compared with the use of natural cannabis, the use of SCRAs may cause more frequent and more severe unwanted negative effects, especially in younger, inexperienced users. Psychosis and psychosis-like conditions seem to occur relatively often following the use of SCRAs, presumably due to their high potency and the absence of CBD in the preparations. Studies on the relative risk of SCRAs compared with natural cannabis to induce or evoke psychosis are urgently needed.

8 September 2010 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
TBTibor Markus Brunt
Tibor Markus Brunt
APAnneke Poortman
Anneke Poortman
RNRaymond Jm Niesink
Raymond Jm Niesink
WBWim van Den Brink
Wim van Den Brink
Recently, several reports have indicated instability of the ecstasy market in the Netherlands and other EU countries. In the current study, we demonstrate this instability in the Netherlands, showing a decrease of ecstasy tablets containing 3,4-methylenedioxymetamphetamine (MDMA) by more than 50% in 2009. In addition, we describe a partial replacement of MDMA in tablets sold as ecstasy by a previously unseen substance, mephedrone (or 4-methylmethcathinone). Mephedrone was quantified and ecstasy tablets contained between 96 and 155 mg of this new compound. So far, no studies about mephedrone’s effects have been published. For this study, we gathered information on the acute subjective effects of mephedrone from 70 regular ecstasy users. Overall, the majority of users considered the effects enjoyable. Mephedrone seemed to evoke effects similar to other amphetamine type psychostimulants, including MDMA. In contrast to MDMA, however, mephedrone induced strong feelings of craving in most users. If the unstable ecstasy market situation persists, the potential of mephedrone to substitute for MDMA might be substantial. Mephedrone, sold as ecstasy, is therefore likely to be a valid cause for health concern.

17 February 2016 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
TBTibor Markus Brunt
Tibor Markus Brunt
CNConstanze Nagy
Constanze Nagy
ABAlexander Bücheli
Alexander Bücheli
DMDaniel Martins
Daniel Martins
MUMiren Ugarte
Miren Ugarte
MVMireia Ventura Vilamala
Mireia Ventura Vilamala

1 February 1999 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
YKYvette J. M. de Kok
Yvette J. M. de Kok
SBSteven J. H. Bom
Steven J. H. Bom
TBTibor Markus Brunt
Tibor Markus Brunt
MKMartijn H. Kemperman
Martijn H. Kemperman
EBEllen van Beusekom
Ellen van Beusekom
FCFrans P. M. Cremers
Frans P. M. Cremers
We analysed a Dutch family with autosomal dominant non-syndromic progressive sensorineural hearing loss and mapped the underlying gene defect by genetic linkage analysis to a 11.0 cM region overlapping the DFNA9 interval on chromosome 14q12–q13. Clinically, the Dutch family differs from the original DFNA9 family by a later age at onset and a more clearly established vestibular impairment. A gene that is highly and specifically expressed in the human fetal cochlea and vestibule, COCH (previously described as Coch5B2), was mapped to the DFNA9 critical region. Sequence analysis revealed a 208C→T mutation in the COCH gene, resulting in a Pro51Ser substitution in the predicted protein in all affected individuals of the family but not in unaffected family members and 200 control individuals. The same mutation was also identified in three apparently unrelated families with a similar phenotype, suggesting the presence of a Dutch founder mutation. The function of COCH is unknown but several characteristics of the protein point to a structural role in the extracellular matrix. The mutant serine at position 51 is situated between cysteines and possibly interferes with proper COCH protein folding or its interaction with extracellular matrix proteins.

17 March 2014 in Addiction
Verified
Journal Article
Closed access
PDF file
PPPeggy van der Pol
Peggy van der Pol
NLNienke Liebregts
Nienke Liebregts
TBTibor Markus Brunt
Tibor Markus Brunt
JAJan van Amsterdam
Jan van Amsterdam
RGRon de Graaf
Ron de Graaf
MLMargriet van Laar
Margriet van Laar

1 February 2015 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
LHLaura Hondebrink
Laura Hondebrink
JLJohanna J. Nugteren-Van Lonkhuyzen
Johanna J. Nugteren-Van Lonkhuyzen
DGDaan Van Der Gouwe
Daan Van Der Gouwe
TBTibor Markus Brunt
Tibor Markus Brunt